Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KD-414 (XBB.1.5 or JN.1) pediatric COVID-19 prevention study
jRCT2071230079Active, not recruiting
- Sponsor
- KM Biologics
- Start
- Nov 2023
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing KD-414 vaccine with Placebo (2 arms). Primary endpoint: Incidence of COVID-19 from day 15 to day 105 after second dose. Started Nov 2023; status: active, not recruiting.
02
Drugs
KD-414
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2071230079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071230079.